Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

Item

http://www.wikidata.org/entity/Q36114852

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@ast

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@en

type

Item

label

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@ast

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@en

prefLabel

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@ast

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@en

P1476

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

@en

P2093

Joseph Wahler

http://www.w3.org/2001/XMLSchema#string

Nanjoo Suh

http://www.w3.org/2001/XMLSchema#string

P2860

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3

Humanization of an anti-p185HER2 antibody for human cancer therapy

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

P2888

s40495-015-0040-z

P304

324-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40495-015-0040-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26442201

http://www.w3.org/2001/XMLSchema#string

P932

4591552

http://www.w3.org/2001/XMLSchema#string